GO:0001760 aminocarboxymuconate-semialdehyde decarboxylase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001760 describes the enzymatic decarboxylation of 2-amino-3-carboxymuconate 6-semialdehyde to 2-aminomuconate 6-semialdehyde, a key branch point in tryptophan catabolism.
• The enzyme ACMSD controls whether tryptophan-derived intermediates are routed toward complete oxidation or toward de novo NAD+ synthesis.
• ACMSD activity is regulated by its quaternary structure, with dimeric and higher-order assemblies displaying different catalytic efficiencies.
• ACMSD can also catalyze the enol/keto tautomerization of oxaloacetate, revealing a broader catalytic repertoire beyond its canonical decarboxylase reaction.
• Species-specific differences in ACMSD activity influence NAD+ metabolism and have been documented across animal models [6,8].
• Dietary factors, such as fatty acid composition, can modulate ACMSD activity and gene expression, linking nutrition to NAD+ homeostasis.
Description
Aminocarboxymuconate-semialdehyde decarboxylase (ACMSD) activity, encoded by GO:0001760, is a molecular function that catalyzes the decarboxylation of 2-amino-3-carboxymuconate 6-semialdehyde to 2-aminomuconate 6-semialdehyde and carbon dioxide. This reaction sits at a critical branch point in the kynurenine pathway of tryptophan catabolism, determining whether intermediates are fully oxidized or diverted toward de novo NAD+ biosynthesis. Because NAD+ is essential for mitochondrial function and cellular energy metabolism, ACMSD activity has emerged as a key regulator of healthspan and metabolic resilience. Researchers study this activity to understand how tryptophan flux is partitioned between energy production and NAD+ salvage, and to identify therapeutic opportunities for metabolic and age-related diseases [2,3]. The enzyme is also notable for its structural complexity: ACMSD forms different quaternary assemblies that modulate its catalytic efficiency, making it a compelling model for structure-function studies. Additionally, ACMSD has been shown to catalyze the enol/keto tautomerization of oxaloacetate, suggesting that its catalytic pocket can accommodate chemically diverse substrates. Understanding GO:0001760 therefore bridges enzymology, metabolic regulation, and translational research.
aminocarboxymuconate-semialdehyde decarboxylase activity At A Glance
| GO ID | GO:0001760 |
|---|---|
| GO term | aminocarboxymuconate-semialdehyde decarboxylase activity |
| Ontology | molecular_function |
| Synonym | ACMSD activity; picolinic acid carboxylase activity; alpha-amino-beta-carboxymuconate-epsilon-semialdehyde beta-decarboxylase activity |
| Major function | Decarboxylation of 2-amino-3-carboxymuconate 6-semialdehyde to 2-aminomuconate 6-semialdehyde and CO2 |
| Reaction | 2-amino-3-carboxymuconate 6-semialdehyde + H+ = 2-aminomuconate 6-semialdehyde + CO2 |
| Pathway context | Kynurenine pathway of tryptophan catabolism; branch point affecting de novo NAD+ synthesis |
| Enzyme example | ACMSD (aminocarboxymuconate-semialdehyde decarboxylase) |
What Is GO:0001760?
GO:0001760, aminocarboxymuconate-semialdehyde decarboxylase activity, is defined as the catalysis of the reaction: 2-amino-3-carboxymuconate 6-semialdehyde + H+ = 2-aminomuconate 6-semialdehyde + CO2. In simpler terms, it is the enzyme activity that removes a carboxyl group from a specific tryptophan metabolite, converting it into another intermediate. This activity is synonymous with ACMSD activity, picolinic acid carboxylase activity, and alpha-amino-beta-carboxymuconate-epsilon-semialdehyde beta-decarboxylase activity, reflecting historical names for the same catalytic function.
Why Is aminocarboxymuconate-semialdehyde decarboxylase activity Important in Cell Biology?
GO:0001760 is important because it governs a metabolic decision that influences cellular NAD+ levels, mitochondrial function, and overall metabolic health. By converting 2-amino-3-carboxymuconate 6-semialdehyde to 2-aminomuconate 6-semialdehyde, ACMSD prevents the spontaneous cyclization of the former into quinolinate, a neuroactive and potentially excitotoxic intermediate. This regulation is critical for maintaining the balance between tryptophan catabolism and NAD+ biosynthesis, with direct implications for aging, neurodegeneration, and metabolic disorders [2,3].
• Controls a branch point in tryptophan catabolism that determines NAD+ production versus complete oxidation.
• Regulates levels of quinolinate, a neuroactive metabolite implicated in excitotoxicity.
• Modulates mitochondrial function and healthspan in animal models.
• Exhibits species-specific activity differences that affect NAD+ metabolism [6,8].
• Is influenced by dietary fatty acids, linking nutrition to NAD+ homeostasis.
• Can be inhibited by pyrazinamide-derived metabolites, affecting tryptophan and NAD+ metabolism.
• Displays quaternary-structure-dependent catalytic efficiency, offering insights into allosteric regulation.
• Catalyzes oxaloacetate tautomerization, expanding its potential metabolic roles.
• Represents a potential therapeutic target for metabolic and age-related diseases.
• Serves as a model for studying enzyme evolution and substrate promiscuity.
Molecular Mechanism of aminocarboxymuconate-semialdehyde decarboxylase activity
Substrate Binding and Decarboxylation
In simple terms: The enzyme grabs a specific tryptophan breakdown product and removes a carboxyl group from it.
ACMSD binds 2-amino-3-carboxymuconate 6-semialdehyde and catalyzes the removal of CO2, yielding 2-aminomuconate 6-semialdehyde. This decarboxylation reaction is the defining catalytic event of GO:0001760 and is essential for directing tryptophan metabolites away from quinolinate formation.
Quaternary Structure and Activity Regulation
In simple terms: The enzyme can assemble into different shapes, and these shapes affect how fast it works.
ACMSD forms dimers and higher-order oligomers, and the quaternary structure controls its catalytic activity. This structural plasticity provides a mechanism for regulating ACMSD function in response to cellular conditions, influencing the flux of tryptophan metabolites.
Alternative Substrate: Oxaloacetate Tautomerization
In simple terms: The enzyme can also help a different molecule switch between two forms.
Beyond its canonical decarboxylase reaction, ACMSD catalyzes the enol/keto tautomerization of oxaloacetate. This finding suggests that ACMSD may have additional roles in metabolic regulation beyond tryptophan catabolism, potentially linking it to central carbon metabolism.
Inhibition by Pyrazinamide Metabolites
In simple terms: Certain drugs can block this enzyme, changing how the body processes tryptophan.
Pyrazinamide, an anti-tuberculosis drug, is metabolized to a potent inhibitor of ACMSD, as demonstrated in rat studies. This inhibition alters tryptophan and NAD+ metabolism, highlighting the pharmacological relevance of GO:0001760.
Species-Specific Differences
In simple terms: Different animals have different levels of this enzyme activity.
ACMSD activity varies across animal species, contributing to differences in tryptophan metabolism and NAD+ synthesis [6,8]. These variations underscore the importance of choosing appropriate model organisms for studying GO:0001760 [6,8].
Key Genes Involved in GO:0001760 aminocarboxymuconate-semialdehyde decarboxylase activity
The following genes and proteins are directly or indirectly associated with aminocarboxymuconate-semialdehyde decarboxylase activity (GO:0001760) and its metabolic context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ACMSD | Encodes the enzyme that catalyzes the decarboxylation reaction | Primary gene for GO:0001760; target for metabolic and NAD+ studies [1,2] |
| QPRT | Converts quinolinate to nicotinate mononucleotide in NAD+ synthesis | Downstream of ACMSD branch point; affects NAD+ flux |
| HAAO | Catalyzes a step in tryptophan catabolism upstream of ACMSD | Context for pathway flux |
| KYNU | Kynureninase, involved in tryptophan catabolism | Upstream enzyme influencing substrate availability |
| TDO2 | Tryptophan 2,3-dioxygenase, initiates kynurenine pathway | Regulates tryptophan flux into the pathway |
| IDO1 | Indoleamine 2,3-dioxygenase, alternative pathway initiator | Influences substrate supply for ACMSD |
| NADSYN1 | NAD+ synthetase, final step of de novo NAD+ synthesis | Downstream of ACMSD; links to NAD+ production |
| NMNAT1 | Nicotinamide mononucleotide adenylyltransferase | NAD+ salvage pathway; interacts with de novo synthesis |
| SIRT1 | NAD+-dependent deacetylase | Senses NAD+ levels influenced by ACMSD activity |
| SIRT3 | Mitochondrial NAD+-dependent deacetylase | Mitochondrial function linked to NAD+ availability |
| PGC-1α | Master regulator of mitochondrial biogenesis | Downstream effector of NAD+ levels |
| TSPYL2 | Testis-specific protein Y-encoded-like 2, implicated in kidney injury | Potential link to ACMSD-related pathways in kidney |
| PYZ | Pyrazinamide, prodrug that inhibits ACMSD | Pharmacological tool to modulate ACMSD activity |
| FASN | Fatty acid synthase, influenced by dietary fatty acids | Dietary regulation of ACMSD expression |
| SCD1 | Stearoyl-CoA desaturase, affected by dietary fatty acids | Linked to ACMSD regulation by fatty acids |
| CPT1A | Carnitine palmitoyltransferase 1A, fatty acid oxidation | Metabolic context of ACMSD regulation |
| PPARA | Peroxisome proliferator-activated receptor alpha | Transcription factor potentially regulating ACMSD |
How Is aminocarboxymuconate-semialdehyde decarboxylase activity Regulated?
ACMSD activity is regulated at multiple levels. Its quaternary structure controls catalytic efficiency, with different oligomeric states displaying distinct activities. Dietary fatty acids differentially affect ACMSD activity and gene expression in rat liver, indicating nutritional regulation. Additionally, pyrazinamide-derived metabolites act as potent inhibitors, providing a pharmacological means of regulation. Species-specific differences further modulate ACMSD activity levels [6,8].
aminocarboxymuconate-semialdehyde decarboxylase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ACMSD | Metabolic disorders, mitochondrial dysfunction | ACMSD knockout mouse; overexpression in cell lines |
| ACMSD | Neurodegeneration, excitotoxicity | Neuronal cell lines with ACMSD knockdown |
| TSPYL2 | Kidney injury | TSPYL2 knockout kidney cells |
| ACMSD | NAD+ deficiency | ACMSD KO models supplemented with NAD+ precursors |
| ACMSD | Drug-induced metabolic changes | Pyrazinamide-treated rat models |
Metabolic and Mitochondrial Disorders
ACMSD activity influences de novo NAD+ synthesis, and its modulation enhances mitochondrial function and improves health in animal models. Dysregulation of this pathway may contribute to metabolic disorders characterized by mitochondrial dysfunction.
Neurodegeneration and Excitotoxicity
By diverting 2-amino-3-carboxymuconate 6-semialdehyde away from quinolinate formation, ACMSD limits the production of a neuroactive metabolite that can cause excitotoxicity. Reduced ACMSD activity could therefore increase vulnerability to neurodegenerative conditions.
Kidney Injury
TSPYL2, a protein implicated in kidney injury, may interact with pathways related to ACMSD, suggesting a potential role for tryptophan-NAD+ metabolism in renal pathology.
Pharmacological Interactions
Inhibition of ACMSD by pyrazinamide metabolites alters tryptophan and NAD+ metabolism, which may contribute to drug side effects or therapeutic outcomes.
From aminocarboxymuconate-semialdehyde decarboxylase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ACMSD loss alter NAD+ levels? | ACMSD knockout cell lines or mouse models |
| How does quaternary structure affect ACMSD activity? | Point mutations disrupting oligomerization |
| Can ACMSD be targeted to boost NAD+? | Knock-in of hyperactive ACMSD variants |
| What is the role of ACMSD in specific tissues? | Tissue-specific overexpression or knockout |
| How do dietary factors regulate ACMSD? | Dietary intervention in wild-type and KO animals |
| Does ACMSD inhibition mimic pyrazinamide effects? | CRISPR knockout of ACMSD in hepatocytes |
How to Study the aminocarboxymuconate-semialdehyde decarboxylase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic assay | ACMSD catalytic activity | Kinetic studies, inhibitor screening |
| X-ray crystallography | Three-dimensional structure | Quaternary structure determination |
| LC-MS/MS metabolomics | Tryptophan and NAD+ metabolites | Pathway flux analysis |
| RT-qPCR | ACMSD mRNA expression | Dietary or genetic regulation |
| Western blot | ACMSD protein levels | Validation of expression changes |
| CRISPR knockout | Loss of ACMSD function | Phenotypic studies |
| Overexpression | Gain of ACMSD function | NAD+ enhancement studies |
| Tautomerization assay | Oxaloacetate enol/keto ratio | Alternative substrate characterization |
Enzymatic Activity Assays
Direct measurement of ACMSD activity using substrate 2-amino-3-carboxymuconate 6-semialdehyde and monitoring product formation by spectrophotometry or HPLC [1,3].
Structural Biology
X-ray crystallography and cryo-EM to determine ACMSD quaternary structure and substrate binding.
Metabolomics
LC-MS/MS to quantify tryptophan metabolites, NAD+, and related intermediates in cells or tissues with altered ACMSD expression.
Gene Expression Analysis
RT-qPCR and RNA-seq to measure ACMSD mRNA levels under different conditions, such as dietary fatty acid supplementation.
How CRISPR Can Be Used to Study GO:0001760 aminocarboxymuconate-semialdehyde decarboxylase activity
Knockout
CRISPR-Cas9 knockout of ACMSD can be used to eliminate its decarboxylase activity, leading to accumulation of upstream metabolites and reduced NAD+ synthesis. This model helps assess the contribution of GO:0001760 to metabolic phenotypes.
Point Mutation
Introducing point mutations in ACMSD that disrupt oligomerization or catalytic residues allows researchers to dissect the relationship between quaternary structure and activity.
Knock-in
Knock-in of tagged or variant ACMSD alleles enables tracking of protein localization and function in vivo, as well as testing of hyperactive or inactive variants [1,2].
Overexpression
Overexpression of ACMSD in cell lines or tissues can boost NAD+ levels and improve mitochondrial function, providing a gain-of-function model for therapeutic studies.
How EDITGENE Supports aminocarboxymuconate-semialdehyde decarboxylase activity Research
Researchers studying aminocarboxymuconate-semialdehyde decarboxylase activity-related genes often need to determine whether a candidate gene is causally involved in metabolic regulation, NAD+ homeostasis, or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for aminocarboxymuconate-semialdehyde decarboxylase activity research.
Frequently Asked Questions About aminocarboxymuconate-semialdehyde decarboxylase activity
What is aminocarboxymuconate-semialdehyde decarboxylase activity?
It is the enzymatic activity defined by GO:0001760 that catalyzes the decarboxylation of 2-amino-3-carboxymuconate 6-semialdehyde to 2-aminomuconate 6-semialdehyde and CO2.
What gene encodes aminocarboxymuconate-semialdehyde decarboxylase?
The ACMSD gene encodes the enzyme responsible for this activity.
What is the role of ACMSD in NAD+ synthesis?
ACMSD diverts tryptophan metabolites away from quinolinate, influencing de novo NAD+ synthesis.
How is ACMSD activity regulated?
It is regulated by quaternary structure, dietary fatty acids, and inhibitors such as pyrazinamide metabolites [1,4,7].
What diseases are associated with ACMSD dysfunction?
Metabolic disorders, neurodegeneration, and kidney injury have been linked to altered ACMSD activity [2,5].
Can ACMSD catalyze other reactions?
Yes, ACMSD can also catalyze the enol/keto tautomerization of oxaloacetate.
Are there species differences in ACMSD activity?
Yes, ACMSD activity varies across animal species, affecting tryptophan metabolism [6,8].
How can I study ACMSD activity in the lab?
Enzymatic assays, metabolomics, and CRISPR knockout models are commonly used [1,2].
What is the GO ID for this activity?
The GO ID is GO:0001760.
What are synonyms for this activity?
Synonyms include ACMSD activity, picolinic acid carboxylase activity, and alpha-amino-beta-carboxymuconate-epsilon-semialdehyde beta-decarboxylase activity.
Conclusion
GO:0001760, aminocarboxymuconate-semialdehyde decarboxylase activity, is a critical enzymatic function at the intersection of tryptophan catabolism and NAD+ biosynthesis. Its regulation by quaternary structure, diet, and inhibitors underscores its importance in metabolic health and disease [1,2,4,7]. Studying this activity with CRISPR-based models offers promising avenues for therapeutic intervention in metabolic and neurodegenerative disorders.
References
- 1. Yang Y et al.. 2019. Quaternary structure of α-amino-β-carboxymuconate-ϵ-semialdehyde decarboxylase (ACMSD) controls its activity.. J Biol Chem 294(30):11609-11621 PMID: 31189654
- 2. Katsyuba E et al.. 2018. De novo NAD(+) synthesis enhances mitochondrial function and improves health.. Nature 563(7731):354-359 PMID: 30356218
- 3. Yang Y et al.. 2024. α-Amino-β-carboxymuconate-ε-semialdehyde decarboxylase catalyzes enol/keto tautomerization of oxaloacetate.. J Biol Chem 300(11):107878 PMID: 39395800
- 4. Nasu S et al.. 1981. The effect of pyrazines on the metabolism of tryptophan and nicotinamide adenine dinucleotide in the rat. Evidence of the formation of a potent inhibitor of aminocarboxy-muconate-semialdehyde decarboxylase from pyrazinamide.. Biochim Biophys Acta 677(1):109-19 PMID: 6794644
- 5. Sui M et al.. 2024. The role of Testis-Specific Protein Y-encoded-Like 2 in kidney injury.. iScience 27(5):109594 PMID: 38665207
- 6. Allegri G et al.. 2003. Kynurenine pathway enzymes in different species of animals.. Adv Exp Med Biol 527:455-63 PMID: 15206763
- 7. Egashira Y et al.. 2004. Differential effects of dietary fatty acids on rat liver alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase activity and gene expression.. Biochim Biophys Acta 1686(1-2):118-24 PMID: 15522828
- 8. Allegri G et al.. 2003. Enzyme activities of tryptophan metabolism along the kynurenine pathway in various species of animals.. Farmaco 58(9):829-36 PMID: 13679176
